Despite significant scientific knowledge in the field of cancer immunology, therapeutic strategies using cancer vaccines to generate anti-tumor immunity have historically resulted in only modest clinical benefit. Disappointing results from prior cancer vaccine trials are likely due to multifactorial causes. Perhaps the most important is the role of inherent tumor-induced immune suppression and enhanced immunologic tolerance. Current research directed toward understanding the mechanisms of immunologic tolerance has led to the development of promising therapeutic immune regulatory antibodies that inhibit immunologic checkpoints and subsequently enhance immunologic anti-tumor activity. This review discusses the prior challenges associated with cancer vaccines and describes how, by breaking immune inhibition and facilitating immune stimulation, immune regulatory antibodies show great promise in the treatment of a variety of tumors.
T he origin of cancer immunotherapy can be traced back to the work of Dr William Coley, who, in the 1890s, found that when bacterial products (Coley's toxins) were administered to patients with inoperable cancers, dramatic responses were seen. 1, 2 Although considered unconventional and controversial for years, the principle of harnessing the immune system to treat cancer has ultimately retained great promise. Specific active immunotherapy, through therapeutic cancer vaccines, is a unique approach to cancer therapy by enlisting the patient's own immune system, largely through activation of T cells, to recognize and destroy tumors. It is possible that this approach, based on the immune system's exquisite selectivity, could mount a durable anti-tumor immune response with fewer adverse effects than traditional chemotherapy.
Despite the promise of cancer vaccines, initial trials met numerous challenges that limited their clinical utility. Although the reason for prior disappointing clinical results was likely multifactorial, recent research suggests that important mechanisms involved in immunologic inhibition may be a primary reason previous cancer vaccines failed. Immunotherapeutic modalities, aimed at manipulating these immunologic checkpoints, are now proving indispensable in the field of cancer immunotherapy.
On March 25, 2011 , the U.S. Food and Drug Administration (FDA) approved ipilimumab (Yervoy; Bristol-Myers Squibb, Princeton, NJ) for the treatment of patients with unresectable or metastatic melanoma. Ipilimumab is the first therapy for unresectable or metastatic melanoma to demonstrate a significant improvement in overall survival based on the results of a randomized phase III trial 3 and works by blocking cytotoxic T lymphocyteYassociated antigen 4 (CTLA-4). Inhibition of CTLA-4 enhances anti-tumor immunity by preventing inhibitory signals that would otherwise down-regulate T-cell activation. The FDA's recent approval of ipilimumab exemplifies the promise immunomodulatory antibodies provide. It also validates the use of interleukin-2 (IL-2) (aldesleukin), which should be rightfully considered as the first effective therapy for melanoma, which relies solely on immune modulation and has no direct effect on the tumor. This review focuses on the challenges experienced in the development of therapeutic cancer vaccines and how novel strategies to modulate the immune system, particularly through abrogation of immune inhibitory mechanisms and enhancement of costimulatory pathways, are reason to retain great optimism for the future.
TYPES OF CANCER VACCINE PLATFORMS, ASSOCIATED CHALLENGES, AND CLINICAL RESULTS
A variety of approaches have been used in vaccine development with the goal of inducing clinically relevant anti-tumor immune responses, each found to have particular challenges. Perhaps the simplest cancer vaccine strategy consists of a peptide/ small epitope vaccine delivered intradermally or subcutaneously with an immunologic adjuvant. 4 Cloning of a number of shared melanoma-associated antigens and cancer-testis antigens (i.e., MAGE-1, MAGE-3), expressed specifically by solid tumors, generated enthusiasm for peptide/small epitope vaccination trials to elicit specific anti-tumor immunity. 5 Unfortunately, peptide/ small epitope vaccines combined with incomplete Freund adjuvant were insufficiently immunogenic and did not elicit robust anti-tumor immunity in the absence of exogenous cytokines. 6 A prior phase III trial for patients with resected, high-risk melanoma in the adjuvant setting compared GM2-ganglioside versus interferon >2B. Patients treated with interferon >2B, as opposed to the GM2-ganglioside vaccine, had improved relapse-free and overall survival. 7 One phase II trial for patients with metastatic melanoma showed a high response rate of 42% (13/31 patients) when the peptide vaccine, gp100, was combined with IL-2. 8 Other phase II trials, however, combining gp100 with IL-2, did not demonstrate as high of a response rate. 9 Despite varying results in prior phase II studies of the gp100 vaccine in combination with IL-2, the benefit of combining gp100 with IL-2 appears promising as suggested by the recent favorable results of a randomized phase III trial. 10 In this study, patients with advanced melanoma who received IL-2 in combination with gp100 vs IL-2 alone had improved clinical response (16% vs 6%, P = 0.03) and progressionfree survival (2.2 vs 1.6 months, P = 0.008), respectively. Overall survival was also improved for patients who received the gp100 vaccine in combination with IL-2, although the result was not statistically significant (17.8 vs 11.1 months, P = 0.06).
Plasmid DNA vaccines, similar to peptide/small epitope vaccines, are another relatively simple cancer vaccine to manufacture. Unlike peptide vaccines, plasmid DNA vaccines do not depend on a particular human leukocyte antigen type because the protein product will be processed in vivo by host antigenpresenting cells (APCs). 11 Unfortunately, many DNA vaccines have faced the challenge of limited immunogenicity in vivo in humans. 12 In some models, the immunogenicity of a particular DNA vaccine could be enhanced by using xenogeneic DNA, a closely related version of the gene from a different species. 13 The xenogeneic plasmid DNA vaccine (Oncept, Merial Ltd, North Brunswick Township, NJ) was shown to improve overall survival in dogs with canine mucosal melanoma and, in fact, became the first therapeutic cancer vaccine licensed in the United States (USDA, 2007). 14 To improve immunogenicity that often limits the efficacy of small epitope and DNA vaccines, recombinant viral and bacterial vaccines have been explored as a way to deliver defined tumor antigens using gene transfer. 15 Although the immunologic potential is high, toxicities and neutralizing immunity to the vector backbone remain significant challenges. Prior phase III trials have not demonstrated a survival benefit with this approach. 17 Dendritic cells (DCs), professional APCs and effective primers of T cells, have been developed as a vaccine platform. Despite their promise, their heterogeneity often complicates clinical development, 17 and they are often defective when obtained from cancer patients. 18, 19 A promising 30% response rate was seen in an early clinical trial of a peptide-pulsed DC vaccination for melanoma, 20 but a subsequent phase III trial disappointingly closed early secondary to clear inferiority of this DC vaccine compared with dacarbazine. 21 Cancer vaccines can be derived from whole tumor cells that deliver a diverse panel of tumor antigens. Because tumor cells are often not inherently immunogenic, tumor cell vaccine approaches require genetic modification or modification of tumor cells with costimulatory molecules, of which granulocyte macrophage colony stimulating factor (GM-CSF) has been shown to be particularly effective. 22, 23 Canvaxin, a tumor cell vaccine, initially displayed clinical promise based on perceived favorable results for patients with stage IV melanoma after complete surgical resection. 24 Unfortunately, the phase III trial was stopped prematurely because of a survival disadvantage compared with observation alone. A second tumor cell vaccine, OncoVax, demonstrated benefits in a phase III trial of 254 patients with resected stages II and III colon cancer. Patients who received OncoVax were shown to have improved recurrencefree survival. Despite this benefit, although available in Europe, financial investment into its developmental program has lagged, and it is still not approved by the FDA. 25, 26 Reniale is another tumor cell vaccine that has demonstrated successful clinical results. A 558-patient, open-label phase III clinical study of Reniale showed decreased risk of disease progression at 5 years for vaccinated patients compared with those observed alone. 27 Significant financial challenges, similar to those facing OncoVax, have been preventing plans for an international, phase III, doubleblind, randomized, placebo-controlled trial to secure regulatory approval. Lastly, Prophage (vitespen; formerly HSPPC-96) is an autologous tumor cellYderived heat shock protein vaccine that has been tested in phase III studies in 2 populations: stage IV melanoma and renal cell carcinoma in the adjuvant setting. 28, 29 Although both studies missed their primary endpoints, retrospective analysis suggested that patients with earlier-stage disease and patients who received a greater number of vaccinations may have experienced benefit, hypotheses that require prospective validation.
RADIOGRAPHIC RESPONSE RATE MAY MISGUIDE POTENTIAL BENEFITS OF IMMUNOTHERAPY
In 2004, the Surgery Branch of the National Cancer Institute reviewed 440 patients treated with a variety of cancer vaccines and showed a disappointingly low overall objective response rate of only 2.6%. 30 An update to the 2004 study was performed in 2011 with a review of an additional 936 patients treated with cancer vaccines since 2004. 31 An objective response rate (not including stable disease) remained similar at 3.6%. The response rate varied somewhat among the various vaccine platforms: 3.7% with peptide vaccines, 4.2% with DC vaccines, 0.9% with recombinant viral vaccines, 2% with tumor cell vaccines, and 6.7% with DNA plasmid vaccines. Although disappointingly low, these response rates are somewhat predictable as early-phase oncology clinical trials, when considered together, have response rates on the order of 3.8% to 11%. 32, 33 Although response rate is important, overall survival is perhaps the most important and least subjective study endpoint in therapeutic oncology trials. Even in the absence of a convincing improvement in disease response rate, some vaccine trials for men with asymptomatic or minimally symptomatic castrate-resistant, metastatic prostate cancer demonstrated an overall survival benefit. 34Y36 Although methodology questions regarding these trials remain, the presence of a survival benefit without a convincing tumor response suggests that the standard oncological Response Evaluation Criteria in Solid Tumors (RECIST) may need to be revised when considering immunotherapeutic approaches.
To address the issue of varied radiographic responses during ipilimumab therapy, the radiographic responses of 487 patients treated on 3 multicenter phase II clinical trials of ipilimumab were analyzed, and 4 patterns were identified: decreased baseline lesions without new lesions, durable stable disease, initial increase in total tumor burden but eventual response, and response of initial lesions with development of new lesions. 37 Interestingly, all patterns of radiographic assessment were associated with favorable survival. Because of these observations, immune-related response criteria (irRC) were proposed to evaluate the benefits of immunotherapy, previously potentially misrepresented by traditional RECIST criteria. The main difference of irRC compared with traditional RECIST criteria is that, by irRC, the development of new lesions is considered part of the ''total tumor burden'' and not immediately as overall progressive disease. Immune-related response criteria are already being used in place of traditional RECIST criteria in current clinical protocols, and prospective validation of irRC's correlation with additional clinical endpoints is ongoing.
CHALLENGES WITH VACCINATION APPROACHES AND PROMISE OF IMMUNE REGULATORY ANTIBODIES
Immunotherapeutic approaches via cancer vaccination alone, as described above, have been disappointing for a number of different reasons. Perhaps the most important is current awareness of the significant role immunosuppressive checkpoints play in halting the desired T-cell tumor reactivity cancer vaccines attempt to achieve.
The immune system has established an elaborate system of self-regulation to prevent against excessively damaging immune responses. Although essential for proper immunologic homeostasis, in the presence of active malignancy, inhibition of immune reactivity may predominate overstimulation. Over the past decade, various immune regulatory circuits that contribute to these immunologic checkpoints have been elucidated. Immune regulatory antibodies that block inhibitory pathways or enhance activating pathways have been developed for clinical use. These regulatory antibodies are revitalizing interest in solid tumor immunotherapy and are resulting in promising clinical outcomes where prior cancer vaccination efforts had traditionally fallen short.
ANTIBODIES THAT ABROGATE IMMUNE INHIBITION

CTLA-4YBlocking Antibodies
The most well studied and clinically advanced immune regulatory antibodies block immunologic checkpoints by targeting CTLA-4. CTLA-4 is a member of the CD28:B7 immunoglobulin superfamily and is normally expressed at low levels on the surface of naive effector T cells and regulatory T (Treg) cells. 38 In response to stimulation of a naive T cell through the T-cell receptor, CTLA-4 localizes to the plasma membrane and competes with CD28 for B7, ultimately turning off T-cell receptor signaling. 39, 40 The immune inhibitory function of CTLA-4 is of vital importance as CTLA-4 j/j mice die within 1 month of birth because of diffuse lymphoproliferation and fatal autoimmune tissue destruction. 41 CTLA-4 is additionally involved in Treg-induced immune inhibition as conditional knockout mice that lack CTLA-4 exclusively in the CD4+Foxp3+ Treg compartment develop systemic lymphoproliferation. 42 Preclinical studies suggested the benefit of CTLA-4 inhibition, particularly in combination with GM-CSF, resulting in regression of tumors in a variety of preclinical models: a SM1 mammary tumor model, 43 a B16 melanoma model, 44 and a transgenic murine prostate cancer model. 45 CTLA-4 inhibition also enhanced other vaccination strategies including those involving a poxvirus vaccine and DNA vaccines such as tyrosine-related protein 2 and prostate-specific membrane antigen. 46, 47 In combination with radiotherapy, CTLA-4 inhibition has also demonstrated promise by inhibiting tumors outside the radiation field in the TSA breast carcinoma and MCA38 colon cancer mouse models. 48 Two human monoclonal antibodies that block CTLA-4 have been developed, tremelimumab (Pfizer, New York, NY) and ipilimumab (Bristol Myers-Squibb). In a phase II trial of 246 patients with metastatic melanoma, tremelimumab was associated with a 21% clinical benefit rate (overall response + stable disease). 49 An 18-patient phase II study of tremelimumabin patients with advanced esophageal and gastric cancer, however, only had 1 patient with a partial response, but remarkably, this patient has experienced a durable response and had remained well at 32.7 months. 50 Further development of tremelimumab for metastatic melanoma was halted in April 2008 after Pfizer discontinued a randomized phase III trial based on interim review results, suggesting that tremelimumab would not demonstrate superiority over standard chemotherapy. These results may have been complicated, however, by an unintentional crossover from chemotherapy to compassionate use ipilimumab. Further development of tremelimumab is under consideration. Ipilimumab, the other human antibody inhibiting CTLA-4, is the first agent to demonstrate an overall survival benefit in a phase III trial for patients with unresectable stage III or stage IV melanoma. 3 In this trial, patients who had progressed on prior therapy were randomized in a 3 : 1 : 1 ratio to receive ipilimumab plus a peptide vaccine (gp100), ipilimumab alone, or the peptide vaccine (gp100) alone as the control arm. Median overall survival in the combination ipilimumab and peptide vaccine arm (10.0 months) was similar to the ipilimumab-alone arm (10.1 months) but significantly better than the peptide-vaccinealone arm (6.4 months, P = 0.003). Based on the results of the phase III trial and expected future promise, ipilimumab was approved by the FDA on March 25, 2011, greatly expanding awareness and access of this promising therapeutic antibody.
In a recently completed trial for previously untreated unresectable or metastatic melanoma, ipilimumab (10 mg/kg) in combination with dacarbazine was recently shown to demonstrate superior overall survival (11.2 months) to dacarbazine alone (9.1 months). Survival at 1, 2, and 3 years was higher for the ipilimumab and dacarbazine combination group compared with dacarbazine alone for a hazard ratio for death with combination ipilimumab and dacarbazine of 0.72 (P G 0.001). 51 An additional phase III trial of ipilimumab in the adjuvant setting for resected high-risk melanoma is ongoing (NCT00636168).
Although ipilimumab has been most thoroughly studied in melanoma, ipilimumab has shown promising efficacy in a variety of additional malignancies. A phase II study in patients with metastatic renal cell carcinoma demonstrated that 5 of 40 patients met criteria for a partial response by RECIST criteria. 52 Patients with castrate-resistant, metastatic prostate cancer have been shown to have a decrease in prostate-specific antigen and response in visceral metastases in response to ipilimumab in combination with GM-CSF. 53 Unlike prior cancer vaccine approaches that attempted to elicit T-cell immunoreactivity against a specific tumor antigen, CTLA-4 inhibition causes generalized immunoreactivity. It is expected, therefore, that this may remain an encouraging therapeutic strategy in a variety of additional malignancies as monotherapy or in combination with relevant, tumor-specific vaccination strategies.
Programmed Death 1 Blocking Antibodies
Although CTLA-4 inhibition remains the most thoroughly investigated and clinically developed strategy for abrogating peripheral tolerance, programmed death 1 (PD-1) is another inhibitory receptor and promising therapeutic target. PD-1 is expressed on T cells, B cells, and myeloid cells after activation, 54 and its ligands, PD-L1 and PD-L2, are expressed on APCs, tumor cells, and other cells found in the inflammatory microenvironment. 55 Interaction between PD-L1 and PD-1 appears to contribute to tumor-induced immune suppression through multiple immunosuppressive pathways including induction of T-cell death and enhancement of resistance of tumor cells to T cellY mediated apoptosis. 56, 57 High levels of PD-L1 correlate with poor clinical outcomes in a variety of tumors including pancreatic, ovarian, renal, urothelial, head and neck, and melanoma. 58Y64 Two PD-1 inhibitory antibodies have been developed and tested in clinical trials: CT-011 (Cure Tech, Yavne, Israel) and BMS-936558 (previously MDX-1106; Bristol-Myers Squibb). 65Y67 Results from these trials suggest that these antibodies are well tolerated and can result in disease response in patients with solid tumors. A phase II trial of 21 patients with treatment-refractory metastatic non-small cell lung cancer, renal cell carcinoma, melanoma, or prostate cancer shows that treatment with MDX-1106 demonstrated activity in patients with renal cell carcinoma and melanoma without serious toxicity. 66 In addition to immune regulatory antibodies directly targeting PD-1, an alternative strategy has involved targeting the PD-1 ligand, PD-L1. Research involving a preclinical murine model of leukemia has shown that an antiYPD-L1 antibody resulted in decreased tumor burden and prolonged survival. 68 Clinical trials using MDX-1105, an antiYPD-L1 antibody, are ongoing.
Associated Adverse Effects of Immune Checkpoint Inhibiting Antibodies
As expected, immune regulatory antibodies that block inhibitory checkpoints, such as antiYCTLA-4 and antiYPD-1, have been associated with a spectrum of immune-related adverse effects, traditionally termed immune-related adverse events (irAEs). The most commonly reported adverse events after antiYCTLA-4 inhibition include diarrhea/colitis, dermatitis/rash, vomiting, nausea, and fatigue. 69 Enterocolitis is the most threatening inflammatory condition associated with CTLA-4 inhibition and was seen in 15% of patients with melanoma treated with ipilimumab at 10 mg/kg. 70 Following the recent approval of ipilimumab and its expected widespread use, early recognition and treatment of potentially life-threatening enterocolitis will be essential. Fortunately, corticosteroids can be extremely effective in managing this unique toxicity, and studies have not shown high-dose steroids compromise responses to ipilimumab. 71 In cases of steroid refractory enterocolitis, tumor necrosis factor > blockade with infliximab has been effective. 72 Autoimmune hypophysitis is another less frequent irAE occurring in 5% of 163 patients treated with ipilimumab in one study. 73 Some patients in this study required steroid and/or hormonal therapy, and in some cases, the condition was irreversible.
Patients who experience irAEs appear to derive grater benefit from antiYCTLA-4 therapy. In a phase I study, all 3 responding patients (1 complete response and 2 partial responses) had grade III/IV toxicities. Only 3 of 11 nonresponders had similar toxicities. 74 Further support for the association between irAEs and clinical benefit has been seen in larger studies. 71, 75 Monitoring for predisposition to the development of these irAEs and attempting to separate the therapeutic benefits of antiYCTLA-4 therapy from irAEs are areas of ongoing investigation.
Although PD-1 inhibitory antibody therapy can be additionally associated with immune-mediated adverse effects, its profile of adverse effects is somewhat unique from those associated with CTLA-4 inhibition. Preclinical work has shown that PD-1 genetic knockout mice develop organ-specific autoimmunity, such as dilated cardiomyopathy, nephritis, and arthritic changes. 76, 77 In a phase I trial of the PD-1Yinhibiting antibody, CT-011, no maximum tolerated dose was reached at doses up to 6 mg/kg. 65 This was similar to results for another PD-1 antibody, MDX-1106, as no maximum tolerated dose was reached at doses up to 10 mg/kg. 67 Only 1 patient developed arthritis, and 2 patients developed asymptomatic increase of thyroid stimulating hormone in a subsequent phase II trial of 21 patients who received an antibody directed against PD-1. 66 Pneumonitis may be another rare adverse effect, which is relatively unique to PD-1 blockade.
ANTIBODIES THAT ENHANCE IMMUNE STIMULATION
CD40 Agonist Antibodies
In addition to immune regulatory antibodies that break peripheral tolerance, immune regulatory antibodies that enhance stimulatory pathways are an additional area of great promise.
CD40, a member of the TNF receptor superfamily, is expressed on APCs, endothelial cells, and platelets. Activation by its ligand, CD40L, located on activated T cells, enhances effective tumor immunity by ''licensing'' the APC for T-cell activation, substituting for T-cell ''help,'' 78 and possibly preventing tumorinduced apoptosis of DCs. 79 Given the promise of CD40 agonist therapy in improving tumor immunity, several CD40 agonist, immune-stimulating antibodies have been developed.
CP-870,893 (Pfizer) is a fully human IgG2 antibody that has been tested in phase I clinical trials in patients with solid tumors. Compared with ipilimumab and antiYPD-1 antibodies, a much lower dose was tolerated, with the most common adverse effect being a cytokine release syndrome associated with chills, fever, and rigors. Although 1 trial with CP-870,893 alone in repetitive doses showed only stable disease with no responses, 80 another with a single administration of CP-870,893 reported that 27% of the melanoma patients experienced a partial response at day 43. 81 CP-870,893 was tested in 21 patients with surgically unresectable pancreatic ductal carcinoma. 82 Results indicated that 4 of 21 patients had a partial response, and 11 of 21 had stable disease in this traditionally difficult to treat malignancy. The mechanism of CP-870,893's therapeutic effects is believed to involve the activation of tumor-associated macrophages, illustrating the important role of immunologic manipulation of the tumor microenvironment. A second CD-40 agonist antibody, dacetuzumab, has demonstrated safety and efficacy in a phase I study of patients with recurrent or refractory non-Hodgkin lymphoma. 83 
4-1BB
4-1BB is another member of the TNF receptor superfamily and a marker of T-cell activation. Preclinical work suggests that 4-1BB functions to enhance antigen-specific T-cell activity, and 4-1BB agonist antibodies can facilitate regression of established murine tumors. 84 A phase I dose escalation trial involving patients with refractory cancer has explored the use of a 4-1BB agonist antibody; of 47 patients with melanoma, 3 patients achieved a partial response, and 6 patients experienced stable disease. 85 Recent development, however, has slowed because of 2 cases of fatal hepatic toxicity.
Glucocorticoid-Induced Tumor Necrosis Factor Receptor FamilyYRelated Gene
A third member of the TNF receptor superfamily, glucocorticoid-induced tumor necrosis factor receptor familyY related gene (GITR), is a type I transmembrane protein expressed on inactive T cells and up-regulated following T-cell activation. 86 Ligation of GITR enhances immunity by providing a costimulatory signal that enhances T-cell proliferation and effector functions as well as inhibits the immune suppressive effects of regulatory T cells. 87 Research in preclinical models has demonstrated that ligation of GITR by the monoclonal antibody, DTA-1, at the time of inoculation with a poorly immunogenic tumor led to the rejection of a secondary challenge with the same tumor. 88 Enhanced primary and recall CD8+ T-cell responses, with associated increases in tumor immunity, has also been observed when vaccination with tumor antigens was combined with GITR ligation. 89 Treatment as monotherapy with an antibody agonist directed at GITR resulted in regression of small, established B16 melanoma tumors. 90 Current phase I trials of GITR ligation for patients with melanoma are underway.
OX-40
Similar to CD-40, 4-1BB, and GITR, OX-40 is another costimulatory molecule belonging to the TNF receptor superfamily. Binding of OX-40 to its ligand augments T-cell function and inhibits the suppressive function of Treg cells. 91Y94 Preclinical data have shown that mice that undergo surgical resection or irradiation of primary sarcomas or lung cancers, respectively, have improved recurrence rate and overall survival if additionally treated with adjuvant OX-40 agonist antibody. 95 In patients with resected colon cancers, high levels of OX-40Ypositive lymphocytes in the tumor were correlated with improved survival. 96 A murine IgG1 monoclonal antibody against OX-40 was prepared and tested in a phase I trial of 20 patients with low overall toxicity. 97 Five patients had evidence of tumor regression not meeting criteria for partial response, and there was a dose-dependent proliferation of CD4+ T-helper cells, CD8+ T cells, and natural killer cells. Because the OX-40 antibody in this study was a murine antibody, antimurine antibodies developed in the treated patients, which likely limited clinical benefit.
SUMMARY AND FUTURE DIRECTIONS OF THERAPEUTIC CANCER IMMUNOTHERAPY
Although years of challenges with cancer vaccines have produced less than optimal clinical results, there is reason for future optimism. It appears that stimulating host immunity, through vaccination alone, is insufficient to engender an effective anti-tumor immune response. Although prior failures are likely due to many reasons, inherent and tumor-induced immunosuppressive mechanisms likely prevented prior attempts at therapeutic cancer vaccination. Current immunomodulatory antibodies that break these inhibitory circuits, such as those directed against CTLA-4 and PD-1, have shown great promise and are indispensable when considering vaccination strategies. Costimulatory antibodies directed at CD40, 41-BB, GITR, and OX-40 additionally may help shift the balance in favor of enhancing immune-mediated anti-tumor effects. Future immunotherapy clinical trials are needed to evaluate novel combinations of immunomodulatory antibodies and combinations of immunomodulatory antibodies with other systemic therapies including chemotherapy and targeted therapy.
